

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Program Number	2023 P 2151-8
Program	Prior Authorization/Medical Necessity
Medication	Lonhala Magnair [®] (glycopyrrolate inhalation solution)*, Yupelri [®]
	(revefenacin inhalation solution)
P&T Approval Date	9/2018, 1/2019, 7/2019, 8/2020, 11/2020, 11/2021, 11/2022, 11/2023
Effective Date	2/1/2024

1. Background:

Lonhala Magnair (glycopyrrolate inhalation solution)* and Yupelri (revefenacin inhalation solution) are nebulized long-acting antimuscarinic (anticholinergic) agents indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

2. Coverage Criteria^a:

A. Initial Authorization

- 1. Lonhala Magnair* will be approved based on <u>all</u> of the following criteria:
 - a. Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD) - AND-
 - b. <u>One</u> of the following:
 - 1) History of failure, contraindication or intolerance to **<u>both</u>** of the following:
 - a) Spiriva[®] Handihaler[®] or Respimat[®] (tiotropium)
 - b) Yupelri (revefenacin inhalation solution)


- OR-

- 2) **<u>Both</u>** of the following:
 - a) Patient is unable to use a metered-dose, dry powder or slow mist inhaler (e.g. Spiriva Respimat) to control his/her COPD due to <u>one</u> of the following:
 - i) Cognitive or physical impairment limiting coordination of handheld devices (e.g., cognitive decline, arthritis in the hands) (Document impairment)
 - ii) Patient is unable to generate adequate inspiratory force (e.g., peak inspiratory flow rate (PIFR) resistance is <60 L/min)

- AND-

b) History of failure, contraindication or intolerance to Yupelri (revefenacin inhalation solution)

© 2023 UnitedHealthcare Services Inc.



2. Lonhala Magnair [package insert]. Marlborough, MA: Sunovian Pharmaceuticals Inc. August 2020.

© 2023 UnitedHealthcare Services Inc.

UnitedHealthcare®

- 3. Yupelri [package insert]. Morgantown, WV: Mylan Specialty L.P.; May 2022.
- 4. Ferguson GT, Goodin T, Tosiello R, et al. Long-term safety of glycopyrrolate/eFlow CS in moderate-to-very severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 5 randomized study. *Respiratory Medicine* 132; 2017:251-60.
- 5. Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized longacting beta2-agonists in patients with COPD: An expert panel consensus. *Chronic Obstr Pulm Dis* 2017; 4(1): 7-20

Program	Prior Authorization/Medical Necessity - Lonhala Magnair, Yupelri
Change Control	
Date	Change
9/2018	New program
1/2019	Added Yupelri to the criteria.
7/2019	Removed ipratropium as a step 1 option, added Yupelri as step 1 option prior to Lonhala Magnair and noted that Lonhala Magnair is typically excluded from coverage.
8/2020	Annual review. Updated references and removed step through Seebri Neohaler due to removal from the market.
10/2020	Formatting update.
11/2021	Annual review. Updated references.
11/2022	Annual review. Removed Incruse Ellipta as a step first-line agent. Updated references.
11/2023	Annual review. Updated references.